FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value

Annals of Oncology

Volumn 20, Issue 7, 2009, Pages 1270-1274

  Markova, J ^a   Kobe, C ^b   Skopalova, M ^c   Klaskova, K ^a   Dedeckova, K ^d   Plutschow A ^b   Eich, H T ^b   Dietlein, M ^b   Engert, A ^b   Kozak, T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF COLOGNE   (Germany)

^c NA HOMOLCE HOSPITAL   (Czech Republic)

^d UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

BEACOPP; Chemotherapy; Hodgkin's lymphoma; PET; Response assessment

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; DRUG FATALITY; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; ETOPOSIDE; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROCARBAZINE; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 67650400649     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn768     Document Type: Article

References (21)

1. Diehl V, Mauch P, Harris NL. Hodgkin's disease. In De Vita V (ed): Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins 2001; 2339-2387.
2. Mauch P, Armitage JP, Diehl V et al. Hodgkin's Disease. Philadelphia, PA: Lippincott Williams & Wilkins 1999.
3. Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al. Long-term causespecific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-3439.
4. Diehl V. Hodgkin disease - from pathology specimen to cure. N Engl J Med 2007; 357: 1968-1971.
5. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
6. deWit M, Bohuslavizki KH, Buchert R et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.
7. Spaepen K, Stroobants S, Dupont P et al. Can positron emission tomography with [18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-278.
8. Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin's disease. Blood 2001; 98: 2930-2934.
9. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59.
10. Hutchings M, Mikhaeel NG, Fields PA et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160-1168.
11. Gallamini A, Rigacci L, Francesco M et al. The predictive value of positron emission tomography scanning after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 475-481.
12. Dann EJ, Bar-Shalom R, Tamir A et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905-909.
13. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
14. Sieber M, Bredenfeld H, Josting A et al. 14-Day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: Results of a pilot study of the german Hodgkin's lymphoma study group. J Clin Oncol 2003; 21: 1734-1739.
15. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25: 571-578.
16. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
17. Gallamini A, Hutchings M, Avigdor A, Polliack A. Early interim PET scan in Hodgkin lymphoma: Where do we stand? Leuk Lymphoma 2008; 49: 659-662.
18. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3389-3994.
19. Mikhaeel NG, Hutchings M, Fields PA et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high grade nonHodgkin lymphoma. Ann Oncol 2005; 16: 1514-1523.
20. Zinzani PL, Tani M, Fanti S et al. Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17: 1296-1300.
21. Picardi M, De Renzo A, Pane F et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with postchemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007; 48: 1721-1727.